e-learning
resources
Munich 2014
Monday, 08.09.2014
Therapy of thoracic tumours: clinical trials and case series
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Symptom-to-treatment intervals in lung cancer
N. Belloumi, N. Ben Salah, S. Toujani, M. Mjid, A. Akad, C. Moussa, A. Hedhli, Y. Ouahchi, B. Louzir, J. Daghfous, N. Mhiri, J. Cherif, M. Beji (Tunis, Tunisia)
Source:
International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Session:
Therapy of thoracic tumours: clinical trials and case series
Session type:
Thematic Poster Session
Number:
2728
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. Belloumi, N. Ben Salah, S. Toujani, M. Mjid, A. Akad, C. Moussa, A. Hedhli, Y. Ouahchi, B. Louzir, J. Daghfous, N. Mhiri, J. Cherif, M. Beji (Tunis, Tunisia). Symptom-to-treatment intervals in lung cancer. Eur Respir J 2014; 44: Suppl. 58, 2728
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Imaging of complicated pneumonia: what is new?
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Imaging of eosinophilic lung disease
Related content which might interest you:
Methilation status in EBUS-NA samples of lung cancer
Source: International Congress 2014 – Improving diagnosis of thoracic tumours
Year: 2014
Lung cancer in women: Is it different?
Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours
Year: 2014
Relationship between risk factors for lung cancer and tumor size
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
Second primary lung cancer in squamous NSCLC patients: The Nancy Biobank's database
Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours
Year: 2014
Evaluation of lung cancer patients with distant organ metastasis
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
The value of miR221 and miR222 as a biomarker in non small cell lung cancer
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Brain metastatic recurrence following radically treated lung cancer; a retrospective analysis
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
Functional impairment of NK cells in non-small-cell lung cancer
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Metabolomic analysis of serum samples from patients with lung cancer
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Comorbitities, responses and survival in pts with NSCLC
Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours
Year: 2014
Safety and efficacy of erlotinib in patients with squamous cell lung cancer
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
Association between leptin and risk of lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer II
Year: 2016
Improving NLST criteria for lung cancer screening
Source: International Congress 2014 – Improving diagnosis of thoracic tumours
Year: 2014
Bronchiolo-alveolar carcinoma- sometimes a difficult diagnosis
Source: International Congress 2014 – Diagnosis, imaging and surgery for thoracic tumours
Year: 2014
Predictors of lung cancer patients delay time in Serbia - a cross-sectional study
Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours
Year: 2014
Assessment of nutritional status in patients with primary lung cancer
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
Lung cancer, has it changed in the last ten years?
Source: International Congress 2015 – Quality management in lung cancer
Year: 2015
Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Lung cancer in England: Trends in survival over the duration of the national lung cancer audit
Source: Annual Congress 2013 –Epidemiology of respiratory disease
Year: 2013
EBUS-TBNA for nodal restaging and relapse in lung cancer
Source: International Congress 2014 – Diagnosis, imaging and surgery for thoracic tumours
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept